Elena Johnson
Bone and soft tissue sarcomas are treated with chemotherapy, surgical excision with a safe margin, and radiation. Although good results have been reported in patients with non-metastatic sarcomas, patients with metastatic or recurring sarcomas continue to have poor outcomes. To battle metastatic or reoccurring sarcomas, new medications or adjustments to existing treatments are required. This special issue included new research and reviews on therapeutic targets, anticancer medicines, immunotherapy, and treatment for patients with bone and soft tissue sarcomas. This special issue included several papers and reviews on aberrant gene expression in bone and soft tissue sarcomas. When Simpson et al. analysed gene expression in canine osteosarcomas and non-tumor tissue, they discovered 1281 significantly differently expressed genes (839 lower and 442 greater gene expression), with qRT-PCR and immunohistochemistry verifying a selection of them. Greither et al. also investigated the role of miR-155-5p and miR-203a-3p expression in soft tissue sarcoma patients' prognosis. In this study, higher miR-155-5p expression was linked to a higher tumour stage, while low miR-203a-3p expression and high miR-155-5p expression were both linked to poor survival in patients with soft tissue sarcomas.
Teile diesen Artikel
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi 